Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16316312 | 0.89 | POLB (0.50) | KDM4ETSHRALDH1A1POLBMAPT | |
| SCHEMBL23468962 | 0.89 | KDM4E (0.70) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL23943291 | 0.85 | MAPK1 (0.41) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL21992376 | 0.82 | POLB (0.46) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL2746170 | 0.81 | KDM4E (0.46) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL8107 | 0.81 | KDM4E (0.71) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL10223283 | 0.80 | POLB (0.44) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL422607 | 0.80 | POLB (0.44) | KDM4EALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL14486557 | 0.79 | RIPK1 (0.46) | KDM4EMAPK1HIF1ATSHRALDH1A1 | |
| SCHEMBL20243892 | 0.79 | KDM4E (0.44) | KDM4EMAPK1HIF1ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220169790-A1 | CARBOHYDRATE LIGANDS THAT BIND TO ANTIBODIES AGAINST GLYCOEPITOPES OF GLYCOSPHINGOLIPIDS | UNIV BASEL (CH) | 2022-06-02 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-20170137393-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | KDM4E 1792/4885MAPK1 3981/4885HIF1A 4060/4885 |
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | KDM4E 1713/4885MAPK1 3145/4885HIF1A 751/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | KDM4E 1713/4885MAPK1 3145/4885HIF1A 751/4885 |
| US-10030004-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | KDM4E 1713/4885MAPK1 3145/4885HIF1A 751/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | KDM4E 1792/4885MAPK1 3981/4885HIF1A 4060/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | KDM4E 3048/4885MAPK1 3507/4885HIF1A 3923/4885 |
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | KDM4E 1713/4885MAPK1 3145/4885HIF1A 751/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | KDM4E 1713/4885MAPK1 3145/4885HIF1A 751/4885 |
| US-20170137393-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | KDM4E 1691/4885MAPK1 3717/4885HIF1A 1634/4885 |
| US-20180208577-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | KDM4E 1713/4885MAPK1 3145/4885HIF1A 751/4885 |
| US-20220169790-A1 | CARBOHYDRATE LIGANDS THAT BIND TO ANTIBODIES AGAINST GLYCOEPITOPES OF GLYCOSPHINGOLIPIDS | SIGLEC7, GALC, GBA1 | KDM4E 3976/4885MAPK1 3057/4885HIF1A 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.